Genetic events in the evolution of thyroid cancer

Journal of Otolaryngology

Volumn 31, Issue 4, 2002, Pages 202-206

  Freeman, Jeremy ^a   Carroll, Camilla ^a   Asa, Sylvia ^a   Ezzat, Shereen ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

p53; ras oncogene; ret PTC oncogene; Thyroid cancer

Indexed keywords

PROTEIN P53; PROTEIN RET;

ANAPLASTIC CARCINOMA; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID CANCER; THYROID CELL; THYROID FOLLICLE CELL; THYROID HYPERPLASIA; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA;

EID: 0036696483     PISSN: 03816605     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2002.21690     Document Type: Article

References (22)

1. Wynford-Thomas D. In vitro models of thyroid cancer [review]. Cancer Surv 1993; 16:115-134.
2. Robbins J, Merino MJ, Boice JD, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991; 115:133-147.
3. Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1997; 3:418-428.
4. Livolsi VA. Surgical pathology of the thyroid gland. Philadelphia: WB Saunders, 1990.
5. Weinberg RA. Tumor suppressor genes. Science 1990; 254:1138-1146.
6. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319:525-532.
7. Levine AJ. The p53 tumor-suppressor gene. N Engl J Med 1992; 326:1350-1352.
8. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry? J Pathol 1992; 166:329-330.
9. Wylie FS, Lemoire NR, Williams ED, et al. Structure and expression of nuclear oncogenes in multistage thyroid tumorigenesis. Br J Cancer 1989; 60:561-565.
10. Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1992; 91:179-184.
11. Zou M, Shi Y, Farid NR. p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 1993; 77: 1054-1058.
12. Hosal SA, Apel RL, Freeman JL, et al. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocrinol Pathol 1997; 8:21-28.
13. Pai EF, Kabsch W, Krengel U, et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 1989; 341:209-214.
14. Suarez HG, du Villard JA, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990; 5:565-570.
15. Fagin JA. Genetic basis of endocrine disease. Molecular defects in thyroid gland neoplasia. J Endocrinol Metab 1992; 75:1398-1400.
16. Ezzat S, Zheng L, Kolenda J, et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 1996; 6:409-416.
17. Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992; 89:1517-1522.
18. Ishizaka Y, Shima H, Sugimura T, et al. Detection of phosphorylated ret/PTC oncogene product in cytoplasm. Oncogene 1992; 7:1441-1444.
19. Wajjwalku W, Nakamura S, Hasegawa Y, et al. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res 1992; 83:671-675.
20. Jhiang SM, Mazzaferri EL. The ret/PTC oncogene in papillary thyroid carcinoma [review]. J Lab Clin Med 1994; 123: 331-337.
21. Sugg SL, Ezzat S, Rosen IB, et al. Distinct multiple ret/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 1998; 83:4116-4122.
22. van der Lean BFAM, Freeman JL, Tsang RW, et al. The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma: evidence for dedifferentiation in tumor progression. Endocrinol Pathol 1993; 4:215-221.